Aqr Capital Management LLC Assembly Biosciences, Inc. Transaction History

Aqr Capital Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.8 - $4.56 $222,087 - $266,504	-58,444 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.33 - $6.63 $173,464 - $265,604	-40,061 Reduced 40.67%	58,444 $269,000
Q4 2020 Feb 16, 2021	BUY	$4.87 - $17.29 $383,483 - $1.36 Million	78,744 Added 398.48%	98,505 $596,000
Q3 2020 Nov 16, 2020	SELL	$15.08 - $27.04 $1,643 - $2,947	-109 Reduced 0.55%	19,761 $325,000
Q2 2020 Aug 17, 2020	BUY	$14.57 - $23.96 $117,667 - $193,500	8,076 Added 68.48%	19,870 $463,000
Q1 2020 May 15, 2020	BUY	$10.27 - $21.23 $121,124 - $250,386	11,794 New	11,794 $175,000
Q4 2018 Feb 14, 2019	SELL	$19.05 - $36.45 $287,331 - $549,775	-15,083 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$34.41 - $44.23 $281,921 - $362,376	-8,193 Reduced 35.2%	15,083 $560,000
Q2 2018 Aug 14, 2018	SELL	$39.21 - $50.29 $900,340 - $1.15 Million	-22,962 Reduced 49.66%	23,276 $913,000
Q1 2018 May 15, 2018	BUY	$41.7 - $64.16 $396,275 - $609,712	9,503 Added 25.87%	46,238 $2.27 Million
Q4 2017 Feb 14, 2018	BUY	$28.58 - $49.91 $651,452 - $1.14 Million	22,794 Added 163.5%	36,735 $1.66 Million
Q3 2017 Nov 14, 2017	BUY	$23.08 - $34.92 $321,758 - $486,819	13,941	13,941 $487,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.